FormWeb • OLANZapine

Oregon Department of Corrections

Approved Formulary

QR Code

Add Formweb to your mobile device

Android iOS

February P&T meeting minutes have been posted.

Oregon Department of Corrections

Approved Formulary

Search results for:

OLANZapine

OLANZapine

Cell Status NFISA
Exceptions / Designators FORMULARY RESTRICTED TO TABLETS AND IR INJECTION; OLANZAPINE PAMOATE LONG-ACTING INJECTION IS NON-FORMULARY

Brand names: ZYPREXA, ZYPREXA ZYDIS

Form	Strength
POWDER FOR INJECTION, INTRAMUSCULAR	10 mg
TABLET, DISINTEGRATING, ORAL	5 mg; 10 mg; 15 mg; 20 mg
TABLET, ORAL	5 mg; 7.5 mg; 10 mg; 15 mg; 20 mg

Additional Information:

JANUARY 2021 P&T MINUTES

FEBRUARY 2020 P&T MINUTES

NOVEMBER 2015 P&T MINUTES

JUNE 2014 P&T MINUTES

JUNE 2011 P&T MINUTES

MARCH 2011 P&T MINUTES

JANUARY 2011 P&T MINUTES

Last updated: Jul. 7, 2021

Black Box Warning: Mortality in elderly with dementia related psychosis
FDA Drug Safety: FDA Investigating Two Deaths Following Injection
FDA Drug Safety: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns

This site is intended for the staff of Oregon Department of Corrections.
While others may view accessible pages, Oregon Department of Corrections makes no warranty, express or implied,
as to the use of this information outside of Oregon Department of Corrections.

Copyright © 2024 Rpharmy, LLC All Rights Reserved